| 摘要 |
The present invention relates to a lactic acid bacteria strain used for preparation of a medical composition for treating a cardiac and hepatic disease induced by an autoimmune disease, wherein the medical composition comprises Lactobacillus reuteri strain GMNL-263 (GM-263, ADR-1) and a pharmaceutically acceptable carrier, the medical composition is orally administered, and reduces gap junctions between cardiac cells and specifically inhibits matrix metallopeptidase 9 (MMP-9), C-reactive protein (CRP), interleukin-1-beta (IL-1-beta), tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS) and caspase-3. Also claimed are associated medical and lactic acid bacteria-containing compositions. Preferably, the autoimmune disease is systemic lupus erythematosus (SLE). |
